当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:111.97亿  总市值:133.18亿
流通股本:6.30亿   总股本:7.50亿

现金流量表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金2,324,062,415.041,797,650,008.921,219,334,485.03613,167,483.43
收到的税费返还2,095,837.832,002,668.822,002,668.821,348,890.17
收到其他与经营活动有关的现金107,148,248.5574,478,323.2740,380,327.5421,309,163.45
经营活动现金流入的平衡项目0000
经营活动现金流入小计2,433,306,501.421,874,131,001.011,261,717,481.39635,825,537.05
购买商品、接受劳务支付的现金839,384,842.64660,363,395.23484,378,306.22331,661,257.87
支付给职工以及为职工支付的现金680,092,658.5540,974,402.03378,955,962.71214,475,730.01
支付的各项税费179,638,582.99143,674,414.2898,999,225.3775,888,500.61
支付其他与经营活动有关的现金111,315,278.8580,678,571.0553,174,238.7227,468,232.62
经营活动现金流出的平衡项目0000
经营活动现金流出小计1,810,431,362.981,425,690,782.591,015,507,733.02649,493,721.11
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额622,875,138.44448,440,218.42246,209,748.37-13,668,184.06
二、投资活动产生的现金流量:
收回投资收到的现金581,496,756.8501,496,756.8301,496,756.8206,718,985.7
取得投资收益收到的现金24,850,939.5322,623,640.6120,844,816.132,013,580.31
处置固定资产、无形资产和其他长期资产收回的现金净额150,120.77101,405.6343,534.524,717.48
收到的其他与投资活动有关的现金17,405,311.384,417,661.14,417,661.113,617,661.1
投资活动现金流入的平衡项目0000
投资活动现金流入小计623,903,128.48528,639,464.14326,802,768.55222,354,944.59
购建固定资产、无形资产和其他长期资产支付的现金192,721,315.71149,651,195.84104,049,954.3755,878,731.98
投资支付的现金647,351,750426,076,500175,000,00060,000,000
取得子公司及其他营业单位支付的现金90,059,524.1790,059,524.1790,059,524.17-
支付其他与投资活动有关的现金9,200,000---
投资活动现金流出的平衡项目0000
投资活动现金流出小计939,332,589.88665,787,220.01369,109,478.54115,878,731.98
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-315,429,461.4-137,147,755.87-42,306,709.99106,476,212.61
三、筹资活动产生的现金流量:
偿还债务支付的现金6,894,874.696,873,351.146,815,335.38861,696.2
分配股利、利润或偿付利息支付的现金214,330,738.16214,330,468.7285,318.0555,069.95
支付其他与筹资活动有关的现金140,452,284.23112,085,377.8986,701,967.0423,935,585.72
筹资活动现金流出平衡项目0000
筹资活动现金流出小计361,677,897.08333,289,197.7593,602,620.4724,852,351.87
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-361,677,897.08-333,289,197.75-93,602,620.47-24,852,351.87
四、汇率变动对现金及现金等价物的影响8,409,667.4813,801,951.617,779,109.73-6,273,367.27
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-45,822,552.56-8,194,783.6128,079,527.6461,682,309.41
加:期初现金及现金等价物余额2,899,469,580.532,899,469,580.532,899,469,580.532,899,469,580.53
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额2,853,647,027.972,891,274,796.933,027,549,108.172,961,151,889.94
补充资料:
净利润391,552,561.64-89,508,170.24-
资产减值准备31,232,454.2-238,299.75-
固定资产和投资性房地产折旧89,132,459.75-44,201,261.24-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧89,132,459.75-44,201,261.24-
无形资产摊销14,225,238.1-6,949,277.57-
长期待摊费用摊销15,600,503.29-6,955,970.43-
递延收益摊销-6,188,742.65---
处置固定资产、无形资产和其他长期资产的损失65,951.85---
固定资产报废损失184,920.51-115,150.46-
公允价值变动损失245,641,516.85-197,670,941.47-
财务费用-64,612,672.08--41,139,887.75-
投资损失-9,627,827.07--5,843,535.22-
递延所得税-21,812,197.32--25,651,285.64-
其中:递延所得税资产减少4,257,107.92--653,666.82-
递延所得税负债增加-26,069,305.24--24,997,618.82-
存货的减少239,357,799.14--16,901,754.6-
经营性应收项目的减少-91,412,850.88-26,259,447.86-
经营性应付项目的增加-252,968,657.82--56,899,407.52-
现金的期末余额2,853,647,027.97-3,027,549,108.17-
减:现金的期初余额2,899,469,580.53-2,899,469,580.53-
公告日期2024-03-292023-10-312023-08-312023-04-28
审计意见(境内)标准无保留意见
TOP↑